One-Year Outcomes of Drug-Eluting Balloons versus Drug-Eluting Stents in Diabetic Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Diabetes mellitus is linked with increased risk of restenosis and hostile cardiovascular outcomes following percutaneous coronary intervention (PCI). Drug-eluting stents (DES) are the standard of care, but drug-eluting balloons (DEB) may offer a stentless alternative by delivering antiproliferative drugs locally while avoiding permanent implants. This study involved a systematic review and meta-analysis aimed at assessing the comparative one-year outcomes of DEB versus DES in individuals with diabetes undergoing PCI for de-novo CAD. Methods: The guidelines of PRISMA 2020 are followed in this review. Randomized controlled trials (RCTs) and observational cohort studies reporting diabetic subgroup outcomes were identified through PubMed, Scopus, Web of Science, and Cochrane databases (March 2024). Eligible studies included adults with diabetes (≥18 years) undergoing PCI for de-novo CAD, treated with either DEB or DES, and reporting clinical outcomes at 12 months. Two reviewers independently carried out data extraction and evaluated study quality. Risk of bias in randomized controlled trials was assessed using the Cochrane RoB 2 tool (RCTs), while observational studies were appraised with the Newcastle–Ottawa Scale. For pooled analyses, we utilized RevMan version 5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Results: Twenty studies were included, comprising 6,452 diabetic patients (DEB: 2,890; DES: 3,562). At one year, the occurrence of major adverse cardiovascular events (MACE) was similar between DEB and DES (OR 0.97, 95% CI: 0.77–1.22; p = 0.78; I² = 0%). DEB significantly reduced target lesion revascularization (TLR) compared with DES (OR 0.74, 95% CI: 0.56–0.98; p = 0.04; I² = 19%). No significant differences were observed in target vessel revascularization (TVR; OR 1.00, 95% CI: 0.64–1.55; p = 0.99) or myocardial infarction (MI; OR 1.07, 95% CI: 0.89–1.30; p = 0.47). Assessment through funnel and Galbraith plots demonstrated no discernible evidence of publication bias. However, the trial sequential analysis emphasized that, despite the current findings, additional large-scale, adequately powered randomized trials are warranted to ensure the robustness and reliability of the evidence base. Conclusion: DEB are non-inferior to DES for MACE and MI and superior in reducing TLR in diabetic patients undergoing PCI for de-novo CAD. They represent a safe and effective alternative to DES, particularly in patients at high risk of restenosis or bleeding. Large-scale randomized trials, especially with newer sirolimus-coated DEB, are warranted to confirm long-term efficacy
Fields of Study & Subjects
Coronary Interventions and Diagnostics
Antiplatelet Therapy and Cardiovascular Diseases
Peripheral Artery Disease Management
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 4 March 2026
- Language
- EN